Within the tumor microenvironment, WARS2 expression was predominantly enriched in malignant epithelial (cancer) cells, with minor expression observed in fibroblasts and endothelial cells, and minimal expression across immune cell types (Figures 6C–E). This evidence concerns the gene WARS2 and neoplasm.